l General Information |
Product Name | Erlotinib hydrochloride |
General description | Erlotinib hydrochloride is a quinazoline derivative and antineoplastic agent that functions as a protein kinase inhibitor for EGFR associated tyrosine kinase. |
Synonym | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride; Tarceva; OSI-744 |
Purity | ≥99%(HPLC) | CAS Number | 183319-69-9 |
Formula | C22H24ClN3O4 | Molecular Weight | 429.901 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to pale yellow solid |
Solubility(25℃) | DMSO | ~4mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. |
Application | 1. Antineoplastic Agents 2. Protein Kinase Inhibitors |
l Packaging & Storage |
Packaging | 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
